127 related articles for article (PubMed ID: 1421439)
1. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.
Pourtier-Manzanedo A; Didier AD; Muller CD; Loor F
Anticancer Drugs; 1992 Aug; 3(4):419-25. PubMed ID: 1421439
[TBL] [Abstract][Full Text] [Related]
2. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
3. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
Boesch D; Loor F
Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109
[TBL] [Abstract][Full Text] [Related]
4. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
Boesch D; Muller K; Pourtier-Manzanedo A; Loor F
Exp Cell Res; 1991 Sep; 196(1):26-32. PubMed ID: 1879470
[TBL] [Abstract][Full Text] [Related]
5. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.
Jachez B; Nordmann R; Loor F
J Natl Cancer Inst; 1993 Mar; 85(6):478-83. PubMed ID: 8095304
[TBL] [Abstract][Full Text] [Related]
6. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
7. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
[TBL] [Abstract][Full Text] [Related]
8. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.
Tiberghien F; Loor F
Anticancer Drugs; 1996 Jul; 7(5):568-78. PubMed ID: 8862725
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Lehne G; De Angelis P; den Boer M; Rugstad HE
Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of verapamil, cyclosporin A and SDZ PSC 833 on rhodamine 123 transport and cell cycle in vinblastine-resistant Chinese hamster ovary cells overexpressing P-glycoprotein.
Pétriz J; Sánchez J; Bertrán J; García-López J
Anticancer Drugs; 1997 Oct; 8(9):869-75. PubMed ID: 9402314
[TBL] [Abstract][Full Text] [Related]
11. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
12. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
13. [SDZ PSC 833: a novel modulator of MDR].
Covelli A
Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
[TBL] [Abstract][Full Text] [Related]
14. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D
Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277
[TBL] [Abstract][Full Text] [Related]
16. SDZ 280-125: a cyclopeptolide endowed with an in vitro cyclosporin A-like profile of activity for the reversion of the P-glycoprotein-mediated multidrug resistance of tumor cells.
Jachez B; Boesch D; Emmer G; Loor F
Anticancer Drugs; 1994 Jun; 5(3):313-20. PubMed ID: 7919456
[TBL] [Abstract][Full Text] [Related]
17. Influence of dexniguldipine-HC1 on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers.
Boer R; Haas S; Schödl A
Eur J Cancer; 1994; 30A(8):1117-23. PubMed ID: 7654442
[TBL] [Abstract][Full Text] [Related]
18. Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents.
Jachez B; Cianfriglia M; Loor F
Anticancer Drugs; 1994 Dec; 5(6):655-65. PubMed ID: 7534147
[TBL] [Abstract][Full Text] [Related]
19. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Lehne G; Mørkrid L; den Boer M; Rugstad HE
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
[TBL] [Abstract][Full Text] [Related]
20. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin.
Krishna R; de Jong G; Mayer LD
Anticancer Res; 1997; 17(5A):3329-34. PubMed ID: 9413167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
